🚀 VC round data is live in beta, check it out!
VieMed Valuation Multiples
Discover revenue and EBITDA valuation multiples for VieMed and similar public comparables like Medios, Cerus, TaiDoc Technology, Standard BioTools and more.
VieMed Overview
About VieMed
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
Founded
2016
HQ
Employees
1.2K
Website
Financials (LTM)
EV
$369M
VieMed Financials
VieMed reported last 12-month revenue of $283M and EBITDA of $63M.
In the same LTM period, VieMed generated $162M in gross profit, $63M in EBITDA, and $16M in net income.
Revenue (LTM)
VieMed P&L
In the most recent fiscal year, VieMed reported revenue of $270M and EBITDA of $61M.
VieMed expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $283M | XXX | $270M | XXX | XXX | XXX |
| Gross Profit | $162M | XXX | $155M | XXX | XXX | XXX |
| Gross Margin | 57% | XXX | 58% | XXX | XXX | XXX |
| EBITDA | $63M | XXX | $61M | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 23% | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 8% | XXX | XXX | XXX |
| Net Profit | $16M | XXX | $15M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 6% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
VieMed Stock Performance
VieMed has current market cap of $366M, and enterprise value of $369M.
Market Cap Evolution
VieMed's stock price is $9.49.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $369M | $366M | -3.3% | XXX | XXX | XXX | $0.39 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialVieMed Valuation Multiples
VieMed trades at 1.3x EV/Revenue multiple, and 5.8x EV/EBITDA.
EV / Revenue (LTM)
VieMed Financial Valuation Multiples
As of April 11, 2026, VieMed has market cap of $366M and EV of $369M.
Equity research analysts estimate VieMed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
VieMed has a P/E ratio of 22.8x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $366M | XXX | $366M | XXX | XXX | XXX |
| EV (current) | $369M | XXX | $369M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 5.8x | XXX | 6.0x | XXX | XXX | XXX |
| EV/EBIT | 15.0x | XXX | 16.1x | XXX | XXX | XXX |
| EV/Gross Profit | 2.3x | XXX | 2.4x | XXX | XXX | XXX |
| P/E | 22.8x | XXX | 24.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 30.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified VieMed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
VieMed Margins & Growth Rates
VieMed's revenue in the last 12 month grew by 16%.
VieMed's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
VieMed's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
VieMed's rule of X is 63% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
VieMed Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 10% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 48% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1% | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 50% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
VieMed Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Medios | XXX | XXX | XXX | XXX | XXX | XXX |
| Cerus | XXX | XXX | XXX | XXX | XXX | XXX |
| TaiDoc Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| Standard BioTools | XXX | XXX | XXX | XXX | XXX | XXX |
| Universal Vision | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
VieMed M&A Activity
VieMed acquired XXX companies to date.
Last acquisition by VieMed was on XXXXXXXX, XXXXX. VieMed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by VieMed
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialVieMed Investment Activity
VieMed invested in XXX companies to date.
VieMed made its latest investment on XXXXXXXX, XXXXX. VieMed invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by VieMed
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout VieMed
| When was VieMed founded? | VieMed was founded in 2016. |
| Where is VieMed headquartered? | VieMed is headquartered in United States. |
| How many employees does VieMed have? | As of today, VieMed has over 1K employees. |
| Who is the CEO of VieMed? | VieMed's CEO is Casey Hoyt. |
| Is VieMed publicly listed? | Yes, VieMed is a public company listed on Nasdaq. |
| What is the stock symbol of VieMed? | VieMed trades under VMD ticker. |
| When did VieMed go public? | VieMed went public in 2018. |
| Who are competitors of VieMed? | VieMed main competitors are Medios, Cerus, TaiDoc Technology, Standard BioTools. |
| What is the current market cap of VieMed? | VieMed's current market cap is $366M. |
| What is the current revenue of VieMed? | VieMed's last 12 months revenue is $283M. |
| What is the current revenue growth of VieMed? | VieMed revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of VieMed? | Current revenue multiple of VieMed is 1.3x. |
| Is VieMed profitable? | Yes, VieMed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of VieMed? | VieMed's last 12 months EBITDA is $63M. |
| What is VieMed's EBITDA margin? | VieMed's last 12 months EBITDA margin is 22%. |
| What is the current EV/EBITDA multiple of VieMed? | Current EBITDA multiple of VieMed is 5.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.